RT Journal Article
SR Electronic
T1 What does 16S rRNA gene-targeted next generation sequencing contribute to the study of infective endocarditis in valve tissue?
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.23.21250364
DO 10.1101/2021.01.23.21250364
A1 Paula Santibáñez
A1 Aránzazu Portillo
A1 Sonia Santibáñez
A1 Lara García-Álvarez
A1 María de Toro
A1 José A. Oteo
YR 2021
UL http://medrxiv.org/content/early/2021/01/30/2021.01.23.21250364.abstract
AB Infective endocarditis (IE) is a severe and life-threatening disease. Identification of infectious etiology is essential for establishing the appropriate antimicrobial treatment and decreasing mortality. The aim of this study was to explore potential utility of metagenomics for improving microbiological diagnosis of IE. In this work, next-generation sequencing (NGS) of V3-V4 region of the 16S rRNA gene was performed in 27 heart-valve tissues (18 natives, 5 intravascular devices, and 4 prosthetics) of patients diagnosed by IE. Initial microbiological diagnosis, blood culture (BC) and/or PCR, was compared with NGS-based diagnosis. Metagenomics matched with conventional techniques diagnosis in 24/27 cases (88.9%). The same bacterial family was assigned to 24 cases, the same genus to 23 cases, and the same specie for 13 cases. In 22 of them, the etiological agent was represented by percentages >99% of the reads and in two by ∼70%. Staphylococcus aureus was detected in a previously undiagnosed patient, making the microbiological diagnosis possible in one more sample than with previously used techniques. The remaining two patients showed no coincidence between traditional and NGS microbiological diagnoses. Minority records verified mixed infections in four cases and suggested confections in two cases, supported by clinical data. In conclusion: 16S rRNA gene-targeted NGS allowed to diagnose one case of IE without microbiological entity based on traditional techniques. However, the application of metagenomics to the study of IE in resected heart valves provides no benefits in comparison with BC and/or PCR. More studies are needed before implementation of NGS for the diagnosis of IE.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo specific external funding was available for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval of the regional ethics committee was obtained (Comite Etico de Investigacion Clinica-Consejeria de Sanidad de La Rioja, Ref. CEICLAR PI-19). Informed consent was obtained from all participants. All procedures were in accordance with the ethical standards of the research committee and with the 1964 Helsinki declaration and its later amendments.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are available.